Viking Therapeutics Inc(NASDAQ:VKTX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 21, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.18. The reported EPS was above estimates by 10%. Analysts had estimated an EPS of $-0.2.
Viking Therapeutics Inc (VKTX) made into the market gainers list on Fridays trading session with the shares advancing 0.85% or 0.01 points. Due to strong positive momentum, the stock ended at $1.19, which is also near the day’s high of $1.19. The stock began the session at $1.1622 and the volume stood at 45,562 shares. The 52-week high of the shares is $2.89 and the 52 week low is $0.901. The company has a current market capitalization of $28 M and it has 2,38,25,425 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Nov 15, 2016, Matthew W Foehr (director) purchased 13,000 shares at $1.21 per share price.
Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211 which is an orally available drug candidate under a Phase II clinical trial. Its second clinical program is focused on the development of molecule agonists of the thyroid receptor beta (TRB) for adrenoleukodystrophy (ALD) and lipid disorders such as hypercholesterolemia and non-alcoholic steatohepatitis (NASH). The Company is also engaged in developing VK2809 and VK0214 for the treatment and potential prophylaxis of ALD. Its VK0612 is an orally available Phase IIb-ready drug candidate for type 2 diabetes. The Company’s preclinical programs are focused on identifying erythropoietin receptor (EPOR) agonists for the treatment of anemia and on the development of tissue-selective inhibitors of diacylglycerol acyltransferase-1 (DGAT-1) for the treatment of obesity and dyslipidemia.